自1956年将抗菌的磺胺类衍生物,氨磺丁脲(Carbutamide,BZ55)用于治疗糖尿病后,其他磺脲类的降血糖药如:甲磺丁脲(Tolbutamide,D860)、氯磺丙脲(Chlorpropamide),甲基磺吡啶脲(Tolazamide)及乙酰磺环己脲(Acetohexamide)等相继合成问世。十几年来,为了创造高活性与低毒性的降血糖药,已人工合成了13,300种以上磺酰脲衍生物。1966年报告的HB419(Glibenclamide),就是从中选出的较好药品。自后对该药的药理学和临床应用的报告日益增多。1970年已有正式商品达安疗 Since the anti-bacterial sulfonamide derivative Carbutamide (BZ55) was used to treat diabetes mellitus in 1956, other sulfonylurea hypoglycemic agents such as Tolbutamide (D860), chlorpropamide Chlorpropamide, Tolazamide and Acetohexamide have been successively synthesized. For more than a decade, more than 13,300 sulfonylurea derivatives have been synthesized to create hypoglycemic agents of high activity and low toxicity. HB419 (Glibenclamide), reported in 1966, is the better medicine to choose from. Since then the pharmacology and clinical application of the report increasing. In 1970, there was a formal product Daan treatment